Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.86 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.54 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | APP | P05067 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61517 | 0.93 | CYP2A6 (1.00) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL9789927 | 0.92 | CYP2A6 (0.73) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL28322492 | 0.91 | CYP2A6 (0.95) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| Hydrochloric Acid SCHEMBL6593779 | 0.91 | CYP2A6 (0.95) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| Water SCHEMBL28553448 | 0.91 | CYP2A6 (0.95) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| Biphenyl SCHEMBL11048367 | 0.90 | CYP2A6 (0.76) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| Hydrochloric Acid SCHEMBL20657879 | 0.88 | CYP2A6 (0.91) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| Methyl Alcohol SCHEMBL11054490 | 0.88 | CYP2A6 (0.91) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL2013092 | 0.86 | CYP2A6 (0.86) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 | |
| SCHEMBL21738372 | 0.86 | CYP2A6 (0.86) | CYP2A6CYP2A13ALDH1A1ALDH3A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004807-A | Acrylonitrile compound, preparation method thereof and application thereof in polylactic acid fiber material | 五邑大学 | 2025-05-16 | — | — | CN | claimed |
| CN-111574438-B | Red/near-infrared AIE probe, preparation method thereof and application thereof in detection of Abeta aggregates and fibrotic plaques thereof | 华东理工大学 | 2022-10-18 | — | — | CN | claimed |
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
| CN-120004807-A | Acrylonitrile compound, preparation method thereof and application thereof in polylactic acid fiber material | 五邑大学 | 2025-05-16 | — | — | CN | disclosed |
| EP-3350165-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3350165-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-111574438-B | Red/near-infrared AIE probe, preparation method thereof and application thereof in detection of Abeta aggregates and fibrotic plaques thereof | 华东理工大学 | 2022-10-18 | — | — | CN | disclosed |
| US-20220214351-A1 | FLUORESCENT DYE, PREPARATION METHOD AND USES THEREOF | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220081390-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010054441-A1 | NANOPIGMENTS | NVA IP HOLDINGS PTY LTD (AU) | 2010-05-20 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2002083641-A2 | AMINO-AZA-CYCLOHEXANES FOR THE TREATMENT OF MALARIA | ACTELION PHARMACEUTICALS LTD. (CH) | 2002-10-24 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | CYP2A6 268/4885CYP2A13 477/4885ALDH1A1 290/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP2A6 1119/4885CYP2A13 661/4885ALDH1A1 355/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | CYP2A6 470/4885CYP2A13 258/4885ALDH1A1 2205/4885 |
| US-20220081390-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | CYP2A6 470/4885CYP2A13 258/4885ALDH1A1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.